High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.
Zoe MariñoJuan M Pascasio-AcevedoAdolfo GallegoMoisés DiagoCarme BaliellasRosa MorillasMartín PrietoJosé M MorenoGloria Sánchez-AntolínMercedes VergaraMontserrat FornéInmaculada FernándezMaría A CastroSonia PascualAlexandra GómezLluis CastellsJosé L MonteroJavier CrespoJosé L CallejaJavier García-SamaniegoJose A CarriónAna C ArencibiaAlejandro BlascoCarmen López-NúñezJuan J Sánchez-RuanoFrancisco Gea-RodríguezÁlvaro GiráldezJoaquín CabezasVanessa HontangasXavier TorrasJose CastelloteManuel RomeroJuan TurnesTomás de ArtazaIsidoro NarváezValentín Cuervas-MonsXavier FornsPublished in: Liver international : official journal of the International Association for the Study of the Liver (2017)
In this large cohort of cirrhotic patients managed in the real-world setting in Spain, SOF/SMV±RBV yielded to excellent SVR rates, especially in patients with compensated liver cirrhosis. In addition, this combination showed to be safe, with low rates of SAEs and early discontinuations.